The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study

Flora N Balieva; Andrew Y Finlay; Jörg Kupfer; Lucía Tomas Aragones; Lars Lien; Uwe Gieler; Françoise Poot; Gregor B E Jemec; Laurent Misery; Lajos Kemeny; Francesca Sampogna; Henriët van Middendorp; Jon Anders Halvorsen; Thomas Ternowitz; Jacek C Szepietowski; Nikolay Potekaev; Servando E Marron; Ilknur K Altunay; Sam S Salek; Florence J Dalgard

doi:10.2340/00015555-2918

The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study

Flora N Balieva, Andrew Y Finlay, Jörg Kupfer, Lucía Tomas Aragones, Lars Lien, Uwe Gieler, Françoise Poot, Gregor B E Jemec, Laurent Misery, Lajos Kemeny, Francesca Sampogna, Henriët van Middendorp, Jon Anders Halvorsen, Thomas Ternowitz, Jacek C Szepietowski, Nikolay Potekaev, Servando E Marron, Ilknur K Altunay, Sam S Salek, Florence J Dalgard

Department of Clinical Medicine

7 Citations (Scopus)

Abstract

Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.

Original language	English
Journal	Acta Dermato-Venereologica
Volume	98
Issue number	6
Pages (from-to)	563-569
ISSN	0001-5555
DOIs	https://doi.org/10.2340/00015555-2918
Publication status	Published - Jun 2018

Keywords

Adolescent
Adult
Aged
Cost of Illness
Cross-Sectional Studies
Dermatology/methods
Europe
Female
Humans
Male
Middle Aged
Quality of Life
Remission Induction
Risk Factors
Severity of Illness Index
Skin Diseases/diagnosis
Surveys and Questionnaires
Treatment Outcome
Young Adult

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2340/00015555-2918

Final published version, 358 KBLicence: CC BY-NC

Cite this

Balieva, F. N., Finlay, A. Y., Kupfer, J., Aragones, L. T., Lien, L., Gieler, U., Poot, F., Jemec, G. B. E., Misery, L., Kemeny, L., Sampogna, F., van Middendorp, H., Halvorsen, J. A., Ternowitz, T., Szepietowski, J. C., Potekaev, N., Marron, S. E., Altunay, I. K., Salek, S. S., & Dalgard, F. J. (2018). The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study. Acta Dermato-Venereologica, 98(6), 563-569. https://doi.org/10.2340/00015555-2918

Balieva, FN, Finlay, AY, Kupfer, J, Aragones, LT, Lien, L, Gieler, U, Poot, F, Jemec, GBE, Misery, L, Kemeny, L, Sampogna, F, van Middendorp, H, Halvorsen, JA, Ternowitz, T, Szepietowski, JC, Potekaev, N, Marron, SE, Altunay, IK, Salek, SS & Dalgard, FJ 2018, 'The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study', Acta Dermato-Venereologica, vol. 98, no. 6, pp. 563-569. https://doi.org/10.2340/00015555-2918

@article{df6a3d8b51814c69b4240d5f3904006c,

title = "The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study",

abstract = "Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.",

keywords = "Adolescent, Adult, Aged, Cost of Illness, Cross-Sectional Studies, Dermatology/methods, Europe, Female, Humans, Male, Middle Aged, Quality of Life, Remission Induction, Risk Factors, Severity of Illness Index, Skin Diseases/diagnosis, Surveys and Questionnaires, Treatment Outcome, Young Adult",

author = "Balieva, {Flora N} and Finlay, {Andrew Y} and J{\"o}rg Kupfer and Aragones, {Luc{\'i}a Tomas} and Lars Lien and Uwe Gieler and Fran{\c c}oise Poot and Jemec, {Gregor B E} and Laurent Misery and Lajos Kemeny and Francesca Sampogna and {van Middendorp}, Henri{\"e}t and Halvorsen, {Jon Anders} and Thomas Ternowitz and Szepietowski, {Jacek C} and Nikolay Potekaev and Marron, {Servando E} and Altunay, {Ilknur K} and Salek, {Sam S} and Dalgard, {Florence J}",

year = "2018",

month = jun,

doi = "10.2340/00015555-2918",

language = "English",

volume = "98",

pages = "563--569",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Society for the Publication of Acta Dermato - Venereologica",

number = "6",

}

TY - JOUR

T1 - The Role of Therapy in Impairing Quality of Life in Dermatological Patients

T2 - A Multinational Study

AU - Balieva, Flora N

AU - Finlay, Andrew Y

AU - Kupfer, Jörg

AU - Aragones, Lucía Tomas

AU - Lien, Lars

AU - Gieler, Uwe

AU - Poot, Françoise

AU - Jemec, Gregor B E

AU - Misery, Laurent

AU - Kemeny, Lajos

AU - Sampogna, Francesca

AU - van Middendorp, Henriët

AU - Halvorsen, Jon Anders

AU - Ternowitz, Thomas

AU - Szepietowski, Jacek C

AU - Potekaev, Nikolay

AU - Marron, Servando E

AU - Altunay, Ilknur K

AU - Salek, Sam S

AU - Dalgard, Florence J

PY - 2018/6

Y1 - 2018/6

N2 - Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.

AB - Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.

KW - Adolescent

KW - Adult

KW - Aged

KW - Cost of Illness

KW - Cross-Sectional Studies

KW - Dermatology/methods

KW - Europe

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Quality of Life

KW - Remission Induction

KW - Risk Factors

KW - Severity of Illness Index

KW - Skin Diseases/diagnosis

KW - Surveys and Questionnaires

KW - Treatment Outcome

KW - Young Adult

U2 - 10.2340/00015555-2918

DO - 10.2340/00015555-2918

M3 - Journal article

C2 - 29507999

SN - 0001-5555

VL - 98

SP - 563

EP - 569

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

IS - 6

ER -

The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this